GeoVax Second Quarter 2025 Financial Results and Corporate Update FAQ

What is the main purpose of GeoVax’s announcement on July 28, 2025?

The main purpose is to report GeoVax’s second quarter 2025 financial results and provide a corporate update, including details on their clinical-stage biotechnology developments.

How can I participate in the GeoVax conference call?

Participants can register for the live conference call via the provided links to join either through a webcast on GeoVax’s website or via telephone with a unique passcode and registrant ID.

What time is the GeoVax conference call scheduled?

The conference call is scheduled for 4:30 p.m. ET on July 28, 2025.

Will there be an opportunity to ask questions during the conference call?

Yes, the conference call will include a Q&A session where participants can ask questions.

Where can I find the archived webcast of the conference call?

The archived audio webcast will be available on GeoVax’s website under ‘Events and Presentations’ in the Investor Relations section approximately two hours after the conference call and will remain available for at least 90 days.

What are GeoVax’s lead clinical programs?

GeoVax’s lead clinical programs include GEO-CM04S1, a next-generation COVID-19 vaccine in Phase 2 trials, and Gedeptin®, an oncolytic solid tumor gene-directed therapy, alongside a vaccine targeting Mpox and smallpox progressing directly to a Phase 3 trial.

Who should I contact for more information about GeoVax?

For more information, you can contact GeoVax directly via email at [email protected] or through their Investor Relations at [email protected].

What makes GeoVax’s COVID-19 vaccine candidate unique?

GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients, a booster for specific cancer patients, and a more robust booster for healthy individuals previously vaccinated with mRNA vaccines, addressing gaps in current COVID-19 vaccine coverage.

How does GeoVax plan to advance its Mpox and smallpox vaccine?

Based on recent regulatory guidance, GeoVax anticipates progressing its Mpox and smallpox vaccine directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials.